Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 26, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,396.1692 pence per share.
Material Changes
- Share Repurchase: On March 26, 2007, the Company purchased 3,500,000 ordinary shares of 25 pence each.
- Treasury Holdings: Following this transaction, the Company holds 272,582,678 shares in Treasury.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) is 5,737,688,477. This figure represents the total voting rights and serves as the denominator for disclosure threshold calculations under the Financial Services Authority's rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,737,688,477) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (272,582,678) for assessing potential future buyback capacity or capital management strategies.
- Note that this filing is a regulatory notification of a completed transaction and does not contain operational or financial performance data.